Definition · Plain-language
510(k) clearance
510(k) clearance is the FDA premarket-notification pathway through which most moderate-risk medical devices reach the US market by demonstrating substantial equivalence to a legally marketed predicate device.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
What 510(k) clearance means
A 510(k) is a premarket notification submitted to the FDA before marketing many medical devices, named after the relevant section of the Federal Food, Drug, and Cosmetic Act. Rather than independently proving safety and effectiveness from first principles, the submitter shows that the new device is substantially equivalent to a device already legally on the market, known as a predicate. Most devices going through this route are Class II (moderate risk). When the FDA agrees the case for substantial equivalence is made, it issues a clearance letter — the device is "cleared", not "approved".
The substantial-equivalence standard
Substantial equivalence means the new device has the same intended use as the predicate and either the same technological characteristics, or different characteristics that do not raise new questions of safety and effectiveness and that the submission shows are as safe and effective as the predicate. Demonstrating equivalence may involve performance data, bench testing or, in some cases, clinical data, but the comparison is always anchored to a specific predicate rather than to an absolute evidentiary threshold set independently of any marketed device.
How it differs from PMA
The 510(k) pathway is generally faster and less burdensome than Premarket Approval (PMA), which applies to high-risk Class III devices and requires independent valid scientific evidence of safety and effectiveness. The distinction is reflected in the language: the FDA "clears" a 510(k) device on the basis of equivalence, but "approves" a PMA device after reviewing original safety and effectiveness data. Some low-risk devices are exempt from 510(k) altogether, and novel low-to-moderate-risk devices without a predicate may use the De Novo route.
Key facts
At a glance
- Definition: Premarket notification showing a device is substantially equivalent.
- Named after: Section 510(k) of the Federal Food, Drug, and Cosmetic Act.
- Standard: Substantial equivalence to a legally marketed predicate device.
- Typical class: Most Class II (moderate-risk) devices.
- FDA action: The device is "cleared", not "approved".
- Alternatives: PMA for Class III; De Novo for novel low-to-moderate-risk devices.
Common misconceptions
What people often get wrong
Often heard: A 510(k)-cleared device has been FDA-approved.
Actually: The FDA "clears" a 510(k) device based on substantial equivalence to a predicate; it does not "approve" it. "Approval" is reserved for pathways such as Premarket Approval that review original safety and effectiveness data.
Often heard: 510(k) clearance proves the device is safe and effective on its own evidence.
Actually: Clearance rests on a comparison: the device is shown to be substantially equivalent to a legally marketed predicate. It is not an independent finding of safety and effectiveness in the way a PMA is.
Often heard: Every medical device needs a 510(k).
Actually: Some low-risk devices are exempt from premarket notification, high-risk Class III devices generally require a PMA, and certain novel devices without a predicate use the De Novo classification route instead.
